HCC-UK 2020 Annual Conference
‘Questioning Current Practice’

Thursday 12th March 2020 – Research Afternoon

1300-1330 Registration

1330-1340 Welcome

1340-1530 Scientific Focus 2020 – Hunter Accelerator Award
Chairs: Shish Shetty and Helen Reeves

The Immunosuppressive Niche in HCC – Derek Mann, Newcastle

Decoding HCC immunology by multi-omics - Josep Llovet, Barcelona

NMR spectroscopy with microfluidics – Liver slice applications - Marcel Utz, Southampton

Immunology of the HCC Secretome - Vincenzo Barnaba, Rome

1530 – 1600 Refreshments and posters

1600 – 1710 Multi-centre trials

HUNTER HCC-UK Cohort– sites open, recruitment update - Louise MacDougal

TACE-3 (DEB-TACE and Nivo)- Dan Palmer

Cubic study (CXCR2+Durvalumab) - Jeff Evans

PRIMER-1 Trial - Tim Meyer

The Early Detection of Hepatocellular Liver Cancer [DeLIVER] – Ellie Barnes

1710 – 1800 Basic science papers

Best basic science HCC papers of 2019/20 - Matt Hoare and Tom Bird

*Programme is subject to change
Friday 13th March 2020

0900-0950  Registration

0950-1000  Welcome

1000-1115  Changing practices for early and intermediate HCC  
*Chairs: Vicky Snowdon and Teik Choon See*

HCC Interactive Cases:
HCV-HCC, when to use DAA - *Doug Macdonald*

Who should have SIRT - *Derek Manas*

When to SABR - *James Good*

1115-1145  Refreshments, networking and posters

1145-1230  Changing practices for early HCC  
*Chairs: Abid Suddle and Anya Adair*

Down-staging study report – *Doug Thorburn*, LAG

Change in national allocation - *Alex Gimson*,

Clinical Abstracts 1

Clinical Abstracts 2

1300-1400  Lunch and poster reviewing

1400-1430  Questioning Current Practice - State of art lecture  
*Chair: Aileen Marshall*

Surveillance for HCC – Time to Stratify Risk? - *Helen Reeves*

1430-1520  Oncology – Which Treatment and who for  
*Chairs: Tim Meyer and Bristi Basu*

Locoregional therapy – When to stop – *Abid Suddle*

First line therapy - *Jeff Evans, Glasgow*

*Programme is subject to change
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1520-1540</td>
<td><strong>Refreshments</strong></td>
</tr>
<tr>
<td>1540-1645</td>
<td><strong>Oncology – Which Treatment and who for</strong></td>
</tr>
<tr>
<td></td>
<td>Poster prize presentation – <em>Aileen Marshall</em></td>
</tr>
<tr>
<td></td>
<td>Interactive CASE Evolving systemic therapy in HCC – <em>Bisti Basu</em></td>
</tr>
<tr>
<td></td>
<td>Sequential therapies and clinical trials – <em>Richard Hubner</em></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>1645-1700</td>
<td><strong>Closing Remarks</strong></td>
</tr>
<tr>
<td></td>
<td><em>Aileen Marshall</em></td>
</tr>
</tbody>
</table>

*Programme is subject to change*